Bottom line
IBB vs HTEC: the short answer
IBB (iShares Biotechnology ETF) and HTEC (ROBO Global(R) Healthcare Technology and Innovation ETF) are quite different portfolios: only about 20% of their top holdings (by weight) are shared.
But IBB is far broader, holding 254 positions to 63 for HTEC, so beyond the top names it adds exposure HTEC doesn't have.
IBB is cheaper at 0.44% vs 0.68% — a difference of $24 a year per $10,000 invested.
Over five years, IBB returned +2.5% a year vs −3.9% for HTEC.
Updated Nov 19, 2026
IBB vs HTEC side by side
| IBB | HTEC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | Innovator |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 0.68% |
| Annual cost per $10k | $44 | $68 |
| 10-yr cost on $10k (prospectus) | $555 | $979 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +28.0% | +24.0% |
| 5-yr return (annualized) | +2.5% | −3.9% |
| 10-yr return (annualized) | +4.4% | — |
| Best quarter | +26.8% | +30.7% |
| Worst quarter | −22.9% | −20.8% |
| Net assets (fund) | $5.9B | $69.1M |
| Number of holdings | 254 | 63 |
| Portfolio turnover | 27% | 38% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | HTEC | Difference |
|---|---|---|---|
| 2025 | +28.0% | +24.0% | +4.0% |
| 2024 | −2.4% | +2.8% | −5.2% |
| 2023 | +3.6% | −3.0% | +6.7% |
| 2022 | −13.6% | −33.6% | +20.0% |
| 2021 | +1.0% | −0.2% | +1.2% |
| 2020 | +25.9% | +65.2% | −39.3% |
Source: Fund prospectus bar charts
Holdings overlap
7 of IBB's top 25 holdings also appear in HTEC's top 25.
| Holding | IBB | HTEC |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 1.91% |
| Regeneron Pharmaceuticals, Inc. | 5.70% | 1.97% |
| IQVIA Holdings, Inc. | 3.18% | 2.10% |
| Natera, Inc. | 2.11% | 2.23% |
| Incyte Corp. | 1.62% | 1.80% |
| Illumina, Inc. | 1.41% | 2.09% |
| Medpace Holdings, Inc. | 1.16% | 2.12% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
HTEC top 10
- Caredx, Inc. — 2.68%
- Guardant Health, Inc. — 2.31%
- Natera, Inc. — 2.23%
- Twist Bioscience Corp — 2.23%
- Thermo Fisher Scientific Incorporated — 2.18%
- Medpace Holdings, Inc. — 2.12%
- Adaptive Biotechnologies Corporation — 2.11%
- Iqvia Holdings Inc — 2.10%
- Illumina, Inc. — 2.09%
- Arrowhead Pharmaceuticals, Inc. — 2.08%
FAQ
What is the difference between IBB and HTEC?
Which is cheaper, IBB or HTEC?
Should I own both IBB and HTEC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.